News
Video
Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.
Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the updated survival results of the phase 3 ADAURA trial (NCT02511106) in resectable EGFR-mutant non–small cell lung cancer.